复发性高级别胶质瘤的治疗策略与创新
该综述回顾复发性高级别胶质瘤(含胶质母细胞瘤)的药物治疗证据,涵盖烷化剂、抗血管生成、靶向治疗、免疫治疗、DNA损伤反应与递送策略,并提出以临床试验入组、生物标志物指导、激素管理与生活质量为核心的患者中心算法。
要点
- 复发后中位生存约6-10个月,IDH突变者生存常较好。
- 洛莫司汀、替莫唑胺再挑战和贝伐珠单抗常用但获益有限。
- 靶向药物仅在BRAF V600E、NTRK等特定亚组显示有意义活性。
核心结论
- 尽管总体结局差,靶向、免疫和递送策略的渐进进展支持以临床试验入组、分子分型和症状聚焦照护为核心的患者中心策略。
研究设计与样本
- 综述,回顾烷化剂与抗血管生成治疗、罕见可操作变异的靶向选项、免疫肿瘤联合与细胞治疗、DNA损伤反应/放射增敏策略及血脑屏障调节与局部递送进展,并提出患者中心算法。
主要发现
- 洛莫司汀、替莫唑胺再挑战和贝伐珠单抗仍常用但获益有限。
- 靶向药物仅在BRAF V600E、NTRK等特定亚组显示有意义活性。
- ATM/ATR抑制剂等DDR靶向药物显示早期前景。
- 免疫治疗进展集中于合理联合、溶瘤病毒和局部递送CAR-T/TCR平台。
- 血脑屏障调节策略和适应性试验拓宽了创新疗法的可及性。
关键数值与推荐
- 复发后中位生存约6-10个月。
- 2025年格局包括首个FDA批准用于复发H3K27M突变弥漫性中线胶质瘤的疗法。
临床怎么用
- 优先临床试验入组、生物标志物指导的治疗选择、激素合理使用和生活质量维护。
- 根据分子分型(如BRAF V600E、NTRK)选择靶向治疗。
- 关注血脑屏障调节和局部递送策略以拓宽创新疗法可及性。
局限性
- 本文集中于药物治疗,有意省略了复发时手术和放疗与全身治疗整合之外的扩展讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent high‑grade glioma (HGG)-including glioblastoma-remains lethal, with median survival of approximately 6-10 months after first progression, although patients with IDH mutant tumors often have better survival. Recent ASCO/SNO data and expanding trial data are reshaping available treatment strategies. METHODS: We review evidence for alkylators and anti‑angiogenic therapy; summarize targeted options for rare, actionable alterations; review immuno‑oncology combinations and cellular therapies; highlight DNA damage response (DDR)/radiosensitization strategies and discuss advances in blood-brain barrier modulation and locoregional delivery. We propose a patient‑centered algorithm that prioritizes trial enrollment, biomarker‑guided approaches, steroid stewardship, and quality of life. RESULTS: Lomustine, temozolomide rechallenge, and bevacizumab remain commonly used but provide modest benefit. Targeted agents show meaningful activity only in select subsets (BRAF V600E, NTRK). DDR-directed agents such as ATM/ATR inhibitors show early promise. Immunotherapy advances center on rationale combinations, oncolytic viruses, and locoregionally delivered CAR-T/TCR platforms. Blood-Brain-Barrier (BBB) modulation strategies and adaptive trials are broadening access to innovative therapies. The 2025 landscape features meaningful, if incremental, options-alongside the first ever FDA‑approved therapy for H3K27M‑mutant diffuse midline glioma at relapse-and a pipeline of rational combinatorial approaches poised to refine outcomes for selected patients. This article concentrates on medical options and intentionally omits extended discussions of surgery and radiation beyond their integration with systemic therapies at recurrence. CONCLUSIONS: Despite poor overall outcomes, incremental progress across targeted, immune, and delivery-based approaches supports a patient centered strategy emphasizing clinical-trial enrollment, molecular profiling and symptom focused care.
引用
- Drappatz J, Mantica M. Treatment strategies and innovation for recurrent high-grade glioma. J Neurooncol. 2025. PMID: 41381983. doi:10.1007/s11060-025-05323-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。